Accessibility Menu
NovoCure logo

NovoCure(NASDAQ) NVCR

Market Cap$2.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-0%
5 Year-86%
1 Year+51%
1 Month+14%
Premium Feature
Moneyball Superscore
60/100
$17.67
-2.91%
-0.53Today
NovoCure last closing stock price
MetricPriceDate
Last closeUSD 18.202026-08-19
NovoCure stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.47%USD 17.592026-08-12
1 month+14.18%USD 15.942026-07-20
3 month+1.68%USD 17.902026-05-21
Year to date+40.76%USD 12.932025-12-31
1 year+50.79%USD 12.072025-08-19
3 year-41.38%USD 31.052023-08-18
5 year-86.26%USD 132.432021-08-20
Since inception-0.44%USD 18.282015-10-02

NovoCure Financials at a Glance

Market Cap

$2.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$699.19M

Net Income (TTM)

-$148.57M

EPS (TTM)

-$1.31

P/E Ratio

-13.90

Dividend

$0.00

Beta (Volatility)

1.44 (Average)

Price

$17.67

Volume

394,480.858

Open

$18.12

Previous Close

$18.20

Daily Range

$17.48 - $18.61

52-Week Range

$9.82 - $21.45

Estimated Earnings Date

Oct 29, 2026

NVCR News

TMF-Pills-Purple-StockVStock.png

HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?

Brendan CoffeyJun 24, 2026
TMF-Pills-Blue-StockVStock.png

NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?

Brendan CoffeyJun 22, 2026
TMF-Pills-Blue-StockVStock.png

Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?

Brendan CoffeyJun 19, 2026
SellAlert-Purple.png

CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing

Jake LerchJun 9, 2026
DNA sequencing genome science lab

2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon

Rachel WarrenNov 12, 2025
Foolcom-Featured.png

NovoCure Q2 Revenue Jumps 6 Percent

Motley Fool Markets TeamJul 24, 2025
GettyImages-1477483008

Novocure: Steady Ahead of Key Milestones

Lou WhitemanJul 24, 2025
Person sitting at a desk looking at two monitors

1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street

Prosper Junior BakinyMay 28, 2025
Page 1

NVCR: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NovoCure

NovoCure Limited makes medical devices to treat cancer. Its wearable technology uses electric fields to kill cancer cells. These devices help patients fight tumors while living their lives.

What the Company Makes

  • Optune Gio: Portable device used to treat glioblastoma, which is an aggressive form of brain cancer; generates the majority of revenue.
  • Optune Lua: Therapy for lung cancer and chest lining cancer; generated $5.4 million in revenue in the three months ended June 30, 2026.
  • Optune Pax: Wearable device for treating pancreatic cancer; generated $1.6 million in revenue in the three months ended June 30, 2026.

Strategic Growth and Expansion

  • Submitted the final regulatory application to the FDA in December 2025 seeking approval for treating brain metastases from lung cancer.
  • Received a CE certificate in June 2026 to market Optune Pax for pancreatic cancer in the European Union.
  • Announced national reimbursement coverage in Japan for the use of Optune Lua to treat lung cancer in March 2026.
  • Licensed commercial rights for Greater China to Zai Lab in 2018 to accelerate the development of electric field therapies.

A Unique Approach to Therapy

The company uses a proprietary platform that applies physical forces to disrupt cancer cell division. It manages a global supply chain and is adding production capacity in Mexico and Ireland to increase network resilience.

Key Financial Statistics

  • Net revenue rose 16% to $183.6 million in the three months ended June 30, 2026.
  • Global active patients grew 18% year over year to 5,128 as of June 30, 2026.
  • Gross margin reached 78% in the three months ended June 30, 2026, up from 74% in the same period in 2025.
  • Adjusted EBITDA, a profit measure excluding certain non-cash costs, was $10.8 million in the three months ended June 30, 2026.
  • Cash and short-term investments totaled $440.6 million as of June 30, 2026.

The Bottom Line

NovoCure has transitioned from a clinical-stage developer into a commercial company with multiple approved oncology products. Its focus on expanding into new cancer indications and securing international insurance coverage supports its long-term growth.

AI Generated • Jul 23, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

1,605

CEO

Frank Leonard

Website

www.novocure.com

Headquarters

Baar, 6340, CH

NVCR Financials

Key Financial Metrics (TTM)

Gross Margin

76.13%

Operating Margin

-22.08%

Net Income Margin

-21.25%

Return on Equity

-44.00%

Return on Capital

-24.39%

Return on Assets

-18.68%

Earnings Yield

-7.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

116.45M

Volume

394.48K

Avg. Volume

1.68M

Financials (TTM)

Gross Profit

$532.27M

Operating Income

-$154.40M

EBITDA

-$134.40M

Operating Cash Flow

$1.49M

Capital Expenditure

-$22.62M

Free Cash Flow

-$21.13M

Cash & ST Invst.

$440.56M

Total Debt

$233.42M

NovoCure Performance Analysis

NovoCure annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 537,840,0000.5%
20232023-12-31USD 509,338,000-5.3%
20242024-12-31USD 605,220,00018.8%
20252025-12-31USD 655,353,0008.3%
NovoCure sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.3%
Q42025-12-314.3%
Q12026-03-31-0.2%
Q22026-06-305.5%
NovoCure annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.8856.7%
20232023-12-31USD -1.95120.1%
20242024-12-31USD -1.56-19.6%
20252025-12-31USD -1.22-21.9%
NovoCure sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-308.3%
Q42025-12-3133.3%
Q12026-03-31-181.8%
Q22026-06-3079.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$183.58M

+15.6%

Gross Profit

$142.48M

+21.4%

Gross Margin

77.61%

N/A

Market Cap

$2.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.32M

N/A

Employees

1,605

N/A

Net Income

-$15.66M

+61.0%

EBITDA

-$10.56M

+66.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$440.56M

-51.7%

Total Debt

$233.42M

-66.7%

Accounts Receivable

$145.82M

+13.0%

Inventory

$42.22M

+5.0%

Long Term Debt

$233.42M

+66.2%

Short Term Debt

$0.00

-100.0%

Return on Assets

-18.68%

N/A

Return on Invested Capital

-26.88%

N/A

Free Cash Flow

$5.53M

+125.8%

Operating Cash Flow

$12.44M

+178.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ESTAEstablishment Labs Holdings Inc.
$71.62-4.96%
BLFSBioLife Solutions, Inc.
$37.31+2.30%
AZTAAzenta, Inc.
$36.99+3.86%
NEOGNeogen Corporation
$11.87-2.34%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.83+0.06%
IBITiShares Bitcoin Trust
$41.21+0.06%
SPCXSpace Exploration Technologies
$131.46-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.73-0.05%

Questions About NVCR

What is the current price of NovoCure?

NovoCure is trading at $17.65 per share.

What is the 52-week range for NovoCure?

Over the past 52 weeks, NovoCure has traded between $9.82 and $21.45.

How much debt does NovoCure have?

As of the most recent reporting period, NovoCure reported total debt of $233.42M.

How much cash does NovoCure have on hand?

NovoCure reported $103.62M in cash and cash equivalents in its most recent financial results.

What is NovoCure’s dividend yield?

NovoCure does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services